Why the study?
Does cardiovascular screening effectively reduce sudden cardiac death in the young and add overall healthcare value?
Does cardiovascular screening effectively reduce sudden cardiac death in the young and add overall healthcare value?
The NHLBI Working Group outlines a research agenda to determine the evidence needed to evaluate the efficacy and cost-effectiveness of screening for sudden cardiac death in the young.
Does not yet support routine screening; leaves open the need for prospective trials on efficacy and cost-effectiveness.
The debate over cardiovascular screening to prevent sudden cardiac death in the young (SCDY) has fervent and well-intentioned supporters on both sides.However, this debate will continue unresolved until additional,compelling evidence is provided that either supports orrefutes the utility of screening for SCDY. In an effort to provide direction to determine what type of evidence is necessary and the best methodology to obtain such evidence, the National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group meeting in April 2010 in Bethesda, MD. The charge of the Working Group was to develop a research agenda and identify resources to evaluate whether screening for SCDY would effectively reduce sudden cardiac death and add overall healthcare value, where value was defined as improved clinical outcomes with an acceptable cost-benefit ratio. The Working Group consisted of experts in pediatric cardiology and electrophysiology, adult cardiology, epidemiology, biostatistics, sports medicine, child psychiatry, health economics, ethics, oncology screening, and newborn screening.
No takes yet. Share an insight, caveat, or question.
Kaltman et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: